Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39181242

about

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Establishment of genetically diverse patient-derived xenografts of colorectal cancer.Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.The role of mTOR inhibitors in the treatment of hepatocellular carcinoma.A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin.An autophagy-related gene expression signature for survival prediction in multiple cohorts of hepatocellular carcinoma patients.

P2860

Q26830194-38146F22-D2C7-4159-9712-D1214C1AE160 Q28546221-9B99F1B6-888D-4759-94BC-210695238CE9 Q30841629-7FD5FC82-5434-4B3D-899D-4CDF59EB1D6C Q34704942-D5678441-7AC4-4966-A090-874150AB5446 Q34786480-35A96E4A-B24F-4CED-AC9C-410566F8E854 Q35011302-67645EA0-AC2A-4A3D-A21A-FC6975B36C48 Q35948581-89384FAA-1462-4AF0-85A6-3A76BBC641F0 Q35999766-67188329-5034-42A6-B2AA-DF45A4A2DABE Q36327268-45A8FC96-2F8F-4C20-96B5-C0EFB5A86028 Q36379644-2A2567D5-63C1-4A25-AE6E-A8CE32D03F36 Q36899877-F2E168BC-DDBF-4694-8386-6B6E125BDB4C Q37252398-D06EF557-57F1-439A-94D8-7030A5003AB9 Q37299276-45D5BECF-61AC-46BE-98D5-B33748AD8FBA Q37722656-805D39E1-C40A-4341-9587-5094FCD3DE75 Q39147866-365B0581-8A79-4F05-9725-7697AD1F857C Q45848255-F7E9C743-6E4F-4523-B8D3-36237F3A7601 Q46519493-48776799-B1C4-456D-83C4-6D61375F702B Q54979107-84D22887-868C-4E5E-BA23-F0DC80402CFF Q55411145-36BA673D-A1FF-45C8-B7EC-B098A1813DAA

P2860

Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q39181242

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@en

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@nl

type

label

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@en

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@nl

prefLabel

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@en

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@nl

P1433

Q39181242-95B4E68A-BE7A-4E1E-8365-869D8AA1B4BE

P1476

Q39181242-557F820E-9EE7-4A16-8B31-264686DBC270

P2093

Q39181242-0126F8AD-4227-4EB2-B8EB-3248D633903A

Q39181242-3023C73B-648B-4445-A6B2-E35AB8131592

Q39181242-48A622E2-AC8E-4C8B-91FB-A34A076710C7

Q39181242-53DB146F-08C7-4F6E-B32A-2620075F5212

Q39181242-65061182-4F61-4E24-9484-CDE2CD3079CA

Q39181242-819FBD6B-CE36-418B-A678-8A1B002BC1CF

Q39181242-AF2368D1-DA9F-49D5-9BF9-2CD860305CFD

Q39181242-B696C40C-7927-4138-90F3-50A17E6B528C

Q39181242-E195BA1C-365B-4BFE-9229-4F440750C7A7

Q39181242-E3EAB230-6371-4381-8B49-308BE913EA52

P2860

Q39181242-015941D0-3B94-467E-884C-168F25E13FBA

Q39181242-047AFA93-29BA-426B-8A6D-8956658904C6

Q39181242-04B173F4-C3D2-4045-8DAE-1AE243AB7593

Q39181242-0E04D041-A647-4E56-A7B4-E896A9FBA6AB

Q39181242-108B1CA5-0751-4E21-81E6-9D2D0DE378AE

Q39181242-10AE0A9F-E41A-4B52-A216-3D39E59057A5

Q39181242-1158660E-0E65-4128-85D8-A8D7F4D7DD8E

Q39181242-1448CA08-1389-481B-92B8-AF541A35E577

Q39181242-15D2F5AB-AAA9-4B16-944C-E9F26C1FE18A

Q39181242-1BA8994F-D7C3-49FD-A3D0-7A0F1F5F2264

P304

Q39181242-D127EF6B-8475-4483-9058-7EBF572A0557

P31

Q39181242-3E6F9959-75C1-45B3-B2D3-870F348D6AA2

P356

Q39181242-65A81890-56B0-49E2-B0E8-95881D989F8F

P433

Q39181242-E379F3BF-E48C-4384-B167-3B2426991BEC

P478

Q39181242-8C9C238B-AD0E-44DD-8BBB-3D85CCB9DA2E

P577

Q39181242-7F083BA1-A294-4CCF-BF97-266EB757FC2A

P5875

Q39181242-F7668577-D0C9-4F0C-B443-3B1A62ABB3DE

P698

Q39181242-BD4E91A5-91E8-477E-BBEF-1971FB37F0DE

P356

P1433

Liver International

P1476

Activity of the mTOR inhibitor ...... 0 in hepatocellular carcinoma.

@en

P2093

Aristeidis E Boukouris

http://www.w3.org/2001/XMLSchema#string

Arndt Vogel

http://www.w3.org/2001/XMLSchema#string

Deepika Pothiraju

http://www.w3.org/2001/XMLSchema#string

Florian Kühnel

http://www.w3.org/2001/XMLSchema#string

Jan Hegermann

http://www.w3.org/2001/XMLSchema#string

Johanna Orlik

http://www.w3.org/2001/XMLSchema#string

Jutta Schütt

http://www.w3.org/2001/XMLSchema#string

Laura E Buitrago-Molina

http://www.w3.org/2001/XMLSchema#string

Martha M Kirstein

http://www.w3.org/2001/XMLSchema#string

Michael P Manns

http://www.w3.org/2001/XMLSchema#string

P2860

The use of lead citrate at high pH as an electron-opaque stain in electron microscopy

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Defining the role of mTOR in cancer

The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity

The role of TOR in autophagy regulation from yeast to plants and mammals

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

P304

780-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12126

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236046007

http://www.w3.org/2001/XMLSchema#string

P698

23489999

http://www.w3.org/2001/XMLSchema#string